Randomised phase II trial of chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer. 120 patients will be randomised. Primary end point is pCR; secondary end points safety and biomarker expression before and after therapy.
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial / Guarneri, Valentina; Frassoldati, A; Piacentini, Federico; Jovic, Gordana; Giovannelli, Simona; Oliva, C; Conte, Pierfranco. - In: CLINICAL BREAST CANCER. - ISSN 1526-8209. - STAMPA. - 8:2(2008), pp. 192-194. [10.3816/CBC.2008.n.022]
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial.
GUARNERI, Valentina;FRASSOLDATI A;PIACENTINI, Federico;JOVIC, Gordana;GIOVANNELLI, Simona;CONTE, Pierfranco
2008
Abstract
Randomised phase II trial of chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer. 120 patients will be randomised. Primary end point is pCR; secondary end points safety and biomarker expression before and after therapy.
| File | Dimensione | Formato | |
|---|---|---|---|
|
CHERLOB - CBCancer.pdf
Accesso riservato
Descrizione: Articolo principale
Tipologia:
Versione pubblicata dall'editore
Dimensione
293.12 kB
Formato
Adobe PDF
|
293.12 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
